Marie-Eve Robinson

Dr. Marie-Eve Robinson

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2019 in JBMR Plus
Verified
Journal Article
Open access
PDF file
JTJosephine T. Tauer
Josephine T. Tauer
MRMarie-Eve Robinson
Marie-Eve Robinson
FRFrank Rauch
Frank Rauch
Osteogenesis imperfecta (OI) is a monogenic bone fragility disorder that usually is caused by mutations in one of the two genes coding for collagen type I alpha chains, COL1A1 or COL1A2. Mutations in at least 18 other genes can also lead to an OI phenotype. As genetic testing is more widely used, mutations in these genes are also more frequently discovered in individuals who have a propensity for fractures, but who do not have other typical clinical characteristics of OI. Intravenous bisphosphonate therapy is still the most widely used drug treatment approach. Preclinical studies in OI mouse models have shown encouraging effects when the antiresorptive effect of a bisphosphonate was combined with bone anabolic therapy using a sclerostin antibody. Other novel experimental treatment approaches include inhibition of transforming growth factor beta signaling with a neutralizing antibody and the inhibition of myostatin and activin A by a soluble activin receptor 2B. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research

1 September 2019 in Bone
Verified
Journal Article
Closed access
MRMarie-Eve Robinson
Marie-Eve Robinson
FRFrank Rauch
Frank Rauch

13 January 2020 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MRMarie-Eve Robinson
Marie-Eve Robinson
MSMarc Simard
Marc Simard
ILIsabelle Larocque
Isabelle Larocque
JSJai Shah
Jai Shah
MNMeranda Nakhla
Meranda Nakhla
ERElham Rahme
Elham Rahme
OBJECTIVE: To determine the longitudinal risks of psychiatric disorders in adolescents and emerging adults with versus without diabetes.RESEARCH DESIGN AND METHODS: We conducted a retrospective cohort study in Quebec, Canada, using linked health administrative databases of adolescents (age 15 years) with and without diabetes and without prior psychiatric disorders between 1997 and 2015, followed to age 25 years.RESULTS: Our cohort included 3,544 individuals with diabetes and 1,388,397 without diabetes. Individuals with diabetes were more likely to suffer from a mood disorder (diagnosed in the emergency department or hospital) (adjusted hazard ratio 1.33 [95% CI 1.19–1.50]), attempt suicide (3.25 [1.79–5.88]), visit a psychiatrist (1.82 [1.67–1.98]), and experience any type of psychiatric disorder (1.29 [1.21–1.37]) compared with their peers without diabetes.CONCLUSIONS: Between the ages of 15 and 25 years, the risks of psychiatric disorders and suicide attempts were substantially higher in adolescents and emerging adults with versus without diabetes.

8 August 2019 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
MRMarie-Eve Robinson
Marie-Eve Robinson
HAHaitham AlQuorain
Haitham AlQuorain
MMMonzur Murshed
Monzur Murshed
FRFrank Rauch
Frank Rauch

29 July 2022 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
CGC. Grimbly
C. Grimbly
PEP. Diaz Escagedo
P. Diaz Escagedo
JJJ. L. Jaremko
J. L. Jaremko
ABA. Bruce
A. Bruce
NAN. Alos
N. Alos
LWL. M. Ward
L. M. Ward
Summary Children with sickle cell disease (SCD) have the potential for extensive and early-onset bone morbidity. This study reports on the diversity of bone morbidity seen in children with SCD followed at three tertiary centers. IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications. Introduction To evaluate bone morbidity and the response to intravenous (IV) bisphosphonate therapy in children with SCD. Methods We conducted a retrospective review of patient records from 2003 to 2019 at three Canadian pediatric tertiary care centers. Radiographs, magnetic resonance images, and computed tomography scans were reviewed for the presence of avascular necrosis (AVN), bone infarcts, and myositis. IV bisphosphonates were offered for bone pain management. Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA). Results Forty-six children (20 girls, 43%) had bone morbidity at a mean age of 11.8 years (SD 3.9) including AVN of the femoral (17/46, 37%) and humeral (8/46, 17%) heads, H-shaped vertebral body deformities due to endplate infarcts (35/46, 76%), and non-vertebral body skeletal infarcts (15/46, 32%). Five children (5/26, 19%) had myositis overlying areas of AVN or bone infarcts visualized on magnetic resonance imaging. Twenty-three children (8/23 girls) received IV bisphosphonate therapy. They all reported significant or complete resolution of bone pain. There were no reports of sickle cell hemolytic crises, pain crises, or stroke attributed to IV bisphosphonate therapy. Conclusion Children with SCD have the potential for extensive and early-onset bone morbidity. In this series, IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications.

1 May 2020 in Bone
Verified
Journal Article
Closed access
MRMarie-Eve Robinson
Marie-Eve Robinson
GBGhalib Bardai
Ghalib Bardai
LVLouis-Nicolas Veilleux
Louis-Nicolas Veilleux
FGFrancis H. Glorieux
Francis H. Glorieux
FRFrank Rauch
Frank Rauch